These stocks might not be small for too much longer.
Could Amgen be the next stock to soar due to a GLP-1 drug?
The future keeps getting brighter for these companies.
Its latest medicines for obesity and type 2 diabetes are selling rapidly.
Both of these businesses are finding traction in a pair of major markets.
Eli Lilly just took a page out of Novo Nordisk's book.
These three companies have track records that should please investors.
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects....
This mid-cap biopharma may one day be a titan of the industry.
There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...